News | April 25, 2007

Iapyx Medical Introduces Catheter Stabilization Devices to Minimize Complication, Infections

April 26, 2007 - Iapyx Medical introduced its Stable-Line family of catheter stabilization products designed to minimize the risk of catheter-related bloodstream and urinary tract infections, two of the three most common hospital-acquired infections.

With the launch of Stable-Line Arterial and Stable-Line Foley catheter stabilization devices, Iapyx Medical aims to combat the epidemic of hospital-acquired infections and improve patient care and clinician safety.

The Stable-Line Arterial catheter stabilization device is designed to prevent inadvertent movement and dislodgment of arterial lines. Suture securement, the traditional means of arterial line securement, increases patients' risks of developing catheter-related bloodstream infections (CRBSI), which pose a significant mortality risk.

Suture securement also puts healthcare workers at risk for needlestick injuries, which expose them to blood-borne pathogens including Hepatitis B, Hepatitis C and HIV. The Stable-Line Arterial device mitigates these risks while addressing OSHA's recommendation for sutureless securement and meeting Infusion Nurses Society (INS) standards as a manufactured stabilization device. Without the use of invasive sutures or conventional strips of tape, the Stable-Line Arterial catheter stabilization device firmly grips the extension set to immobilize the catheter while permitting visual inspection and monitoring of the insertion site.

For more information visit www.iapyx.com.

Related Content

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabri
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
FDA says gadolinium retention in the brain is not a safety issue
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for...
Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017
A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has engineered a...
Scientists Develop Novel Chemical Dye to Improve MRI Liver Cancer Imaging
News | Magnetic Resonance Imaging (MRI) | May 03, 2017
May 3, 2017 — Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based ...
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Overlay Init